Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis

Full text
Author(s):
Zheng, Q. [1] ; Wu, H. [2] ; Yu, Q. [3] ; Kim, D. H. (Dennis) [4] ; Lipton, J. H. [4] ; Angelini, S. [5] ; Soverini, S. [6] ; Vivona, D. [7] ; Takahashi, N. [8] ; Cao, J. [1]
Total Authors: 10
Affiliation:
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Clin Res Ctr, Hangzhou 310009, Zhejiang - Peoples R China
[2] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang - Peoples R China
[3] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Surg Oncol, Hangzhou 310003, Zhejiang - Peoples R China
[4] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Chron Myelogenous Leukemia Grp, Toronto, ON - Canada
[5] Univ Bologna, Dept Pharm & Biotechnol, Bologna - Italy
[6] Univ Bologna, Inst Hematol, Dept Expt Diagnost & Specialty Med, Bologna - Italy
[7] Univ Sao Paulo, Fac Ciencias Farmaceut, Dept Anal Clin & Toxicol, Sao Paulo - Brazil
[8] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Akita 010 - Japan
Total Affiliations: 8
Document type: Journal article
Source: PHARMACOGENOMICS JOURNAL; v. 15, n. 2, p. 127-134, APR 2015.
Web of Science Citations: 26
Abstract

Imatinib mesylate, a competitive tyrosine kinase inhibitor, is considered the first-line therapy drug for Ph+ chronic myeloid leukemia (CML). Three single-nucleotide polymorphisms (SNPs) in the ATP-binding cassette, subfamily B (MDR/TAP), member 1 gene (ABCB1/MDR1), c.1236C>T, c.2677G>T/A and c.3435C>T, have been shown to affect cellular transport/metabolism of imatinib. The associations between these SNPs and imatinib response in CML patients have been widely evaluated, but the results were inconsistent. To derive a conclusive assessment of the associations, we performed a meta-analysis by combining data from a total of 12 reports including 1826 patients. The results showed that the 2677G allele or 3435T allele predicted a worse response to imatinib in CML patients, whereas 1236CC genotype was associated with better response in CML patients from Asian region. In conclusion, this meta-analysis suggests that c.1236C>T, c.2677G>T/A and c.3435C>T can be served as predictive markers for the therapeutical use of imatinib in CML patients. (AU)